Case report on a defective antibody response against pneumococcal serotype 9V in a patient with a single episode of pneumonia

Table 1 Pneumococcal antibodies (μg IgG/ml) during pneumonia and after pneumococcal polysaccharide (conjugate) vaccination

	Community-acquired pneumonia		23 V Pneumococcal polysaccharide vaccination (+ 3 months)		13 V Pneumococcal conjugate vaccination (+10 years)
Timeline	Jan–Feb 2005		May–June 2005		July–August 2014
Pneumococcal serotype	Hospital admission (day 1)	Recovery (day 42)	Pre-vaccination	Post-vaccination	Pre-vaccination	Post-vaccination
3	0.12	0.14	0.05	2.43	6.27	13.09
4	0.06	0.03	0.15	0.17	0.02	0.42
6B	0.34	0.33	0.05	0.28	2.63	42.76
9V	0.43	0.25	0.08	0.06	4.06	15.35
14	2.25	2.67	3.21	7.28	6.91	9.55
18C	3.41	4.23	3.76	49.84	39.80	37.41
19F	1.03	1.08	0.60	6.85	31.96	77.10
23F	0.47	0.55	0.47	2.13	1.55	17.29

A sufficient serotype-specific response is defined as having titers higher than 1.3 μg/ml and at least a two-fold increase between pre- and post-vaccination titers [4]
Antibody levels to the infecting pneumococcal serotype (9V) are indicated in bold

ISSN: 2200-6133